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Implications for nursing care 
Signs and symptoms 
 
 
     The most important implication for nursing care is to 
recognize the life threatening airway compromise that 
can accompany ACEi AE, although rare.  Observation of 
the patient for 12 to 24 hours in the ED or via an 
admission to the hospital (Rasmussen, Mey, & Byg, 2014) 
will depend on the severity of the edema and potential 
for airway deterioration.  The practitioner will need to 
recognize that the patient needs taken off of the 
offending medication, and because this type of reaction is 
drug class specific, the patient cannot be put on any other 
ACE inhibitors.  Current research shows that patients can 
usually tolerate angiotension receptor blockers (ARB’s) 
but there have been some reports of a small percentage 
of patients developing AE from these medications also.  
ARB’s are not prescribed as much as ACEi’s which may 
explain the higher rates of AE with ACEi’s. 
     Current recommended treatment for ACEi AE  is that 
the patient needs to be monitored until the swelling 
resolves.  A retrospective analysis by Tai et al. states that 
“90% of  episodes were treated with IV steroids and 
histamine blockers, although not evidence-based and 
ineffective” (Tai, Mascaro, & Goldstein, 2010).  They also 
cite that new therapies are being evaluated with 
kallikrein inhibitors and bradykinin receptor antagonists 
but are not approved yet in the United States for ACEi AE.  
An additional treatment option that has been used with 
some success is fresh frozen plasma which contains ACE 
to break down bradykinin but also contains kininogen, a 
bradykinin substrate (Lewis, 2013).   
     Many studies have tried to correlate risk factors such 
as African American (AA) ethnicity, female sex, diabetes, 
smoking, and alcohol use to give the practitioner 
information to consider about the risk to benefit ratio for 
prescribing ACEi  (Lin, Levine, & Lin, 2013).  AA’s show a 
propensity for bradykinin sensitivity related to 
polymorphisms that call for additional studies (Moholisa, 
et al., 2013).  Conflicting studies through this research 
was that initially diabetics were thought to show some 
protection against this phenomena but other meta-
analysis’ showed maybe this was not accurate, and would 
also need further investigation.   
 
     A 54 year old female patient arrives to the emergency 
department (ED) via squad complaining that 2 days ago her 
lips were tingling and her face felt a little swollen but it 
subsided.  Today she woke up with her tongue protruding out 
of her mouth, her lips, face and eyes are swollen. She does not 
present with itching or urticaria.  Squad personnel established 
an IV, gave her intravenous (IV) Benadryl 50 mg, and 0.3 mg 
subcutaneous epinephrine without any change in her 
condition.  The emergency medical service (EMS) also applied 
oxygen at 2 liters per minute (lpm).   She denies taking any 
new medications or being around any possible new allergens.  
She has a list of her medications and it includes aspirin, 
Metformin, Simvastatin, and Lisinopril, all of which she has 
been on for over a year.  Vital signs are BP 184/110 mm/hg, 
HR 116 bpm, RR 16/min, temporal temperature 98.2 F., and 
SPO2 96% on 2 lpm of oxygen.  Perplexed, the ED staff begins 
their care of this anaphylactic appearing reaction.   
     This presentation to the emergency department has become 
more common and is classic for the diagnosis of ace-inhibitor 
(ACEi) related angioedema.  Although it looks like a histamine 
mediated response, it does not respond to typical emergency 
treatments and is thought to be a bradykinin mediated 
response.  Angioedema is a well recognized adverse effect of 
ACEi and is drug class specific, not dose specific, with 
symptoms appearing from initial dosing to 10 years post 
initiation.  The incidence of ACEi angioedema is 0.1% to 1% 
with 40% of those patients presenting months to years after 
initial dosing (Winters, Rosenbaum, Vilke, & Almazroua, 
2013).  Tai et al. cite a female predominance of 65.7% of 
retrospective reviews, the mean age was 51.8, and racial 
composition was 10.9% Caucasian, 62.4% African American, 
and 14.7% Hispanic (Tai, Mascaro, & Goldstein, 2010).  It is 
prudent that this diagnosis is recognized, the pathophysiology 
understood, and treatment measures taken to control life 
threatening symptoms and prevent future reactions. 
  
 Angioedema (AE) is characterized by nonpitting 
edema of the dermis and subcutaneous layers. The most 
common sites of involvement are the tongue, lips, face, 
and throat.  Airway compromise is rare but drooling, 
stridor, dysphagia, are symptoms that may require 
primary or advanced airway control (see appendix B).  
Swelling can occur in the extremities, genitalia, and 
viscera of the abdomen causing abdominal pain that 
may be unexplained or misdiagnosed with the routine 
testing performed in the ED (Lewis, 2013).  A careful 
history and physical exam can help the practitioner 
differentiate between a histamine mediated reaction 
from a bradykinin mediated angioedema reaction.  
 Known recent exposure to triggers such as certain 
foods, insect stings, sulfa drugs, penicillins, or other 
drug classes can lead a differential diagnosis as 
histamine mediated response.  Rapid onset of the 
swelling accompanied by hives and itching are key 
indicators of an allergic reaction.  Bradykinin mediated 
angioedema is not typically accompanied by urticaria  
(Cicardi, et al., 2014). 
Angiotensin converting enzyme (ACE) is activated by the negative feedback loop of the renin-
angiotensin-aldosterone system (RAAS).  Renin is stimulated in the kidneys by decreased circulating blood 
pressure, serum sodium concentrations, or sensing low renal perfusion; in hypertensive patients this could be from 
renal artery stenosis.  Renin stimulates creation of angiotensinogen I.  Angiotension I is then converted to 
angiotensin II (a potent vasoconstrictor) by ACE in the lungs.  Angiotension II causes vasoconstriction and the 
aldosterone system to stimulate sodium and water retention in the tubules of the kidneys that contributes to the  
increase in blood pressure (Appendix A).  Another function of ACE is that it breaks down the proteins bradykinin, 
aminopeptidase P (which helps inactivate bradykinin among its other functions), and carboxypeptidase 
(Rasmussen, Mey, & Byg, 2014).   
Bradykinin is produced in the kidney from kininogen and functions as potent endothelial 
vasodialator. It releases nitric oxide and prostaglandins, can cause contraction of non-vascular smooth muscle in 
the bronchus (bronchoconstriction), increases vascular permeability, and causes natriuresis contributing to the 
drop in blood pressure (Busse & Buckland, 2012).  
ACE inhibitors interfere with the RAAS by blocking the conversion of angiotensin I to angiotension II 
by inhibiting ACE.  The effect of lower blood pressure is that the vasoconstriction of angiotensin II is blocked and 
the lack of degredation of bradykinin by ACE allows vasodialation.  Eventually angiotensin II levels return to near 
normal as alternative pathways are used for activation and hypertension control is maintained by bradykinin 
mediated vasodialation (Lewis, 2013).   
“Excess bradykinin can act on bradykinin B2 receptors, leading to a change in vascular integrity and 
subsequent edema” (Norman & Holmes, 2012, p. 384).  Substance P, or aminopeptidase P, also accumulates when 
ACE is blocked which causes increased vascular permeability, possible activation of inflammatory processes, and 
edema.  The adaption or maladaption in conjunction with the  increased levels of bradykinin and substance P are 
thought to be the pathophysiology involved in ACEi angioedema. Histamine release may be involved in the 
pathophysiology of ACEi angioedema but common treatment regimines such as antihistamines, histamine blockers, 
steroids, and adrenaline do not markedly improve swelling, therefore, it is unlikely that histamine plays a 
significant role in this form of angioedema (Rasmussen, Mey, & Byg, 2014).  
                                                                                     
 Ace inhibitors are the number one prescribed drug 
class for hypertension.  Since the mid 80’s when they 
started gaining popularity there has been an increase in 
reported ACEi AE.  Patients may be on an ACEi for one 
week to ten years before developing the possibly life 
threatening reaction.  The practitioner must be able to 
recognize the signs and symptoms, understand the 
pathophysiology of this bradykinin mediated edema, and 
know the current recommended treatments.  There 
continues to be discussion about the risk factors and 
increased susceptibility to develop ACEi AE and a risk to 
benefit analysis for each patient.  The practitioner should 
provide anticipatory guidence about these risks, even 
though currently <1% of patients will develop AE, so the 
patient can also recognize an AE episode before it is life 
threatening.   
Conclusion 
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